| Name | Title | Contact Details |
|---|
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
Synthego is a leading provider of genome engineering solutions. Our flagship product, CRISPRevolution, is a portfolio of synthetic guide RNA designed for CRISPR genome editing and research. Synthego`s vision is to bring precision and automation to genome engineering, enabling rapid and cost-effective research with consistent results for every scientist.
Have a Heart`s core mission is to provide the medical, psychological and social benefits of one of the world`s oldest and safest medicines to those in need and to those looking for a safer alternative to alcohol and prescription and illicit drugs. Our goal is to do this in a manner that is innovative, legal and compliant and that provides the most wonderful experience for our guests, our employees and the community overall. We focus on improving the local aesthetic, reducing crime and providing employment to those seeking legitimate employment in the cannabis industry. We believe in providing our customers with the highest quality product in a comfortable, professional and safe environment. All of our locations are unique and have been designed for the comfort and entertainment of our customer. Our friendly and knowledgeable team is always willing to answer any questions, so you`ll find the correct product for your needs. At Have a Heart we have taken many steps to ensure that our customers feel the trust and passion for excellence they deserve.
Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.
Royal Danish Consulate is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.